reviews
P. E. Lønning
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum Ann Oncol (2011)22(3):503-514first published online July 8, 2010 doi:10.1093/annonc/mdq337
Abstract
S. Dawood, S. D. Merajver, P. Viens, P. B. Vermeulen, S. M. Swain, T. A. Buchholz, L. Y. Dirix, P. H. Levine, A. Lucci, S. Krishnamurthy, F. M. Robertson, W. A. Woodward, W. T. Yang, N. T. Ueno, and M. Cristofanilli
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment Ann Oncol (2011)22(3):515-523first published online July 5, 2010 doi:10.1093/annonc/mdq345
Abstract
K. Potthoff, R. Hofheinz, J. C. Hassel, M. Volkenandt, F. Lordick, J. T. Hartmann, M. Karthaus, H. Riess, H. P. Lipp, A. Hauschild, T. Trarbach, and A. Wollenberg
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
Ann Oncol (2011)22(3):524-535first published online August 13, 2010 doi:10.1093/annonc/mdq387
Abstract
F. Turati, C. Galeone, C. La Vecchia, W. Garavello, and A. Tavani Coffee and cancers of the upper digestive and respiratory tracts: meta-analyses of observational studies
Ann Oncol (2011)22(3):536-544first published online October 13, 2010 doi:10.1093/annonc/mdq603
Abstract
ARTICLES
S. Senan, F. Cardenal, J. Vansteenkiste, J. Stigt, F. Akyol, W. De Neve, J. Bakker, J.-M. Dupont, G. V. Scagliotti, U. Ricardi, and J. P. van Meerbeeck
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin–docetaxel, plus radical concurrent chemoradiotherapy with cisplatin–docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer
Ann Oncol (2011)22(3):553-558first published online August 9, 2010 doi:10.1093/annonc/mdq388
Abstract
A.-M. C. Dingemans, A. J. de Langen, V. van den Boogaart, J. T. Marcus, W. H. Backes, H. T. G. M. Scholtens, H. van Tinteren, O. S. Hoekstra, J. Pruim, B. Brans, F. B. Thunnissen, E. F. Smit, and H. J. M. Groen
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
Ann Oncol (2011)22(3):559-566first published online August 11, 2010 doi:10.1093/annonc/mdq391
Abstract
V. Heinemann, D. Di Gioia, U. Vehling-Kaiser, H.-D. Harich, B. Heinrich, A. Welt, C. Ziske, G. Deutsch, R. Pihusch, H. Kölbl, S. Hegewisch-Becker, M. Michl, and H. J. Stemmler
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
Ann Oncol (2011)22(3):603-608first published online August 19, 2010 doi:10.1093/annonc/mdq409
Abstract
A. Schneeweiss, F. Marmé, A. Ruiz, A. G. Manikhas, A. Bottini, M. Wolf, H.-P. Sinn, K. Mansouri, L. Kennedy, and T. Bauknecht
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
Ann Oncol (2011)22(3):609-617first published online August 23, 2010 doi:10.1093/annonc/mdq400
Abstract
H. Nomura, D. Aoki, F. Takahashi, N. Katsumata, Y. Watanabe, I. Konishi, T. Jobo, M. Hatae, M. Hiura, and N. Yaegashi
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)
Ann Oncol (2011)22(3):636-642first published online August 9, 2010 doi:10.1093/annonc/mdq401
Abstract
A. A. Martoni, F. Di Fabio, C. Pinto, P. Castellucci, S. Pini, C. Ceccarelli, D. Cuicchi, B. Iacopino, P. Di Tullio, S. Giaquinta, L. Tardio, R. Lombardi, S. Fanti, and B. Cola
Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer
Ann Oncol (2011)22(3):650-656first published online September 16, 2010 doi:10.1093/annonc/mdq433
Abstract
A. Conconi, G. Martinelli, A. Lopez-Guillermo, P. L. Zinzani, A. J. M. Ferreri, L. Rigacci, L. Devizzi, U. Vitolo, S. Luminari, F. Cavalli, and E. Zucca
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
Ann Oncol (2011)22(3):689695 first published onlinenSeptember 1, 2010 doi:10.1093/annonc/mdq416
Abstract
M. Merlano, E. Russi, M. Benasso, R. Corvò, I. Colantonio, R. Vigna-Taglianti, V. Vigo, A. Bacigalupo, G. Numico, N. Crosetto, M. Gasco, C. Lo Nigro, R. Vitiello, S. Violante, and O. Garrone
Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study Ann Oncol (2011)22(3):712-717 first published online September 1, 2010 doi:10.1093/annonc/mdq412
Abstract
M. Merlano, E. Russi, M. Benasso, R. Corvò, I. Colantonio, R. Vigna-Taglianti, V. Vigo, A. Bacigalupo, G. Numico, N. Crosetto, M. Gasco, C. Lo Nigro, R. Vitiello, S. Violante, and O. Garrone
Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study Ann Oncol (2011)22(3):712-717first published online September 1, 2010 doi:10.1093/annonc/mdq412
Abstract